{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-208100","form_type":"8-K","ticker":"TNGX","cik":"0001819133","company_name":"Tango Therapeutics, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.417488+00:00","generated_at":"2026-06-11T18:49:44.010720+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tango Therapeutics raises $80M in PIPE financing at $5.15 per share","bullets":["Gross proceeds of ~$80M from sale of ~15.5M shares/pre-funded warrants at $5.15/share.","Financing led by Nextech, with participation from Boxer Capital, Bain Capital Life Sciences, Casdin Capital, EcoR1 Capital, Southpoint Capital, Third Rock Ventures, and a large institutional investor.","Proceeds expected to fund operations into 2026; extends runway for PRMT5 programs TNG908 and TNG462, and TNG260 trial.","Pre-funded warrants exercisable at $0.0001, immediately exercisable; company to file resale registration statement by Sep 1, 2023.","Directors and officers subject to 90-day lock-up agreements."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-208100","json":"https://secwatch.observer/filing/0001193125-23-208100.json","markdown":"https://secwatch.observer/filing/0001193125-23-208100.md","text":"https://secwatch.observer/filing/0001193125-23-208100.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819133/000119312523208100/0001193125-23-208100-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819133/000119312523208100/d525614d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:49:44.010720+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"39a8d52b67b5706d2e68d3dd2a0f2ca7a8a9912d","claim":"Tango Therapeutics, Inc. entered into Purchase Agreement with purchasers named therein valued at approximately $80 million (effective 2023-08-10).","evidence_excerpt":"On August 10, 2023 Tango Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of (i) 13,196,671 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at $5.15 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 2,340,579 shares of Common Stock (the “Warrant Shares” and together with the Shares and the Pre-Funded Warrants, the “Securities”), at a purchase price of $5.1499 per Pre-Funded Warrant.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819133/000119312523208100/0001193125-23-208100-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"purchasers named therein"},{"label":"Value","value":"approximately $80 million"},{"label":"Effective","value":"2023-08-10"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}